Pyruvate kinase activators: targeting red cell metabolism in thalassemia

2.

Musallam

KM

,

Cappellini

MD

,

Taher

AT

.

Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia

.

Ann Hematol

.

2021

;

100

(

7

):

1903

-

1905

.

doi:10.1007/s00277-021-04456-5

.

3.

Cappellini

MD

,

Viprakasit

V

,

Taher

AT

, et al;

BELIEVE Investigators

.

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia

.

N Engl J Med

.

2020

;

382

(

13

):

1219

-

1231

.

doi:10.1056/NEJMoa1910182

.

4.

van Dijk

MJ

,

de Wilde

JRA

,

Bartels

M

, et al.

Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: shedding new light on an old enzyme

.

Blood Rev

.

2023

;

61

(

13

):

101103

.

doi:10.1016/j.blre.2023.101103

.

5.

Mettananda

S

,

Gibbons

RJ

,

Higgs

DR

.

α-Globin as a molecular target in the treatment of β-thalassemia

.

Blood

.

2015

;

125

(

24

):

3694

-

3701

.

doi:10.1182/blood-2015-03-633594

.

6.

Guillem

F

,

Dussiot

M

,

Colin

E

, et al.

XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia

.

Haematologica

.

2020

;

105

(

9

):

2240

-

2249

.

doi:10.3324/haematol.2018.210054

.

7.

Longo

F

,

Piolatto

A

,

Ferrero

GB

,

Piga

A.

Ineffective erythropoiesis in β-thalassaemia: key steps and therapeutic options by drugs

.

Int J Mol Sci

.

2021

;

22

(

13

).

doi:10.3390/ijms22137229

.

8.

Fucharoen

S

,

Viprakasit

V.

Hb H disease: clinical course and disease modifiers

.

Hematology Am Soc Hematol Educ Program

.

2009

;

2009

(

1

):

26

–

34

.

doi:10.1182/asheducation-2009.1.26

.

9.

Srinoun

K

,

Sathirapongsasuti

N

,

Paiboonsukwong

K

,

Sretrirutchai

S

,

Wongchanchailert

M

,

Fucharoen

S.

miR-144 regulates oxidative stress tolerance of thalassemic erythroid cell via targeting NRF2

.

Ann Hematol

.

2019

;

98

(

9

):

2045

-

2052

.

doi:10.1007/s00277-019-03737-4

.

10.

Yao

X

,

Xu

L-H

,

Xu

H-G

,

Li

X-Y

,

Liu

Y

,

Fang

J-P

.

Iron metabolism and oxidative status in patients with Hb H disease

.

Hemoglobin

.

2019

;

43

(

1

):

38

-

41

.

doi:10.1080/03630269.2019.1575850

.

11.

Putburee

R

,

Jetsrisuparb

A

,

Fucharoen

S

,

Tripatara

A.

Mitochondrial ferritin expression in erythroid cells from patients with alpha-thalassaemia

.

Hematology

.

2018

;

23

(

10

):

844

-

848

.

doi:10.1080/10245332.2018.1496812

.

12.

Ting

YL

,

Naccarato

S

,

Qualtieri

A

,

Chidichimo

G

,

Brancati

C.

In vivo metabolic studies of glucose, ATP and 2,3-DPG in beta-thalassaemia intermedia, heterozygous beta-thalassaemic and normal erythrocytes: 13C and 31P MRS studies

.

Br J Haematol

.

1994

;

88

(

3

):

547

-

554

.

doi:10.1111/j.1365-2141.1994.tb05072.x

.

13.

Chakraborty

I

,

Mishra

R

,

Gachhui

R

,

Kar

M.

Distortion of β-globin chain of hemoglobin alters the pathway of erythrocytic glucose metabolism through band 3 protein

.

Arch Med Res

.

2012

;

43

(

2

):

112

-

116

.

doi:10.1016/j.arcmed.2012.02.003

.

14.

Rab

MAE

,

van Oirschot

BA

,

van Straaten

S

, et al.

Decreased activity and stability of pyruvate kinase in hereditary hemolytic anemia: a potential target for therapy by AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase

.

Blood

.

2019

;

134

(

suppl 1

):

3506

.

doi:10.1182/blood-2019-129996

.

15.

Matte

A

,

Federti

E

,

Kung

C

, et al.

The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model

.

J Clin Invest

.

2021

;

131

(

10

).

doi:10.1172/JCI144206

.

16.

Mattè

A

,

Kosinski

PA

,

Federti

E

, et al.

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice

.

Haematologica

.

2023

.

doi:10.3324/haematol.2022.282614

(Epub ahead of print).

17.

Taher

A

,

Vichinsky

E

,

Musallam

K

,

Cappellini

MD

,

Viprakasit

V.

Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) [Internet]

.

Weatherall

D

, ed.

Nicosia (Cyprus)

:

Thalassaemia International Federation

;

2013

.

18.

Kuo

KHM

,

Layton

DM

,

Lal

A

, et al.

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study

.

Lancet

.

2022

;

400

(

10351

):

493

-

501

.

doi:10.1016/S0140-6736(22)01337-X

.

19.

Kuo

KHM

,

Layton

DM

,

Lal

A

, et al.

Mitapivat improves markers of erythropoietic activity in long-term study of adults with alpha- or beta-non- transfusion-dependent thalassemia

.

Blood

.

2022

;

140

(

suppl 1

):

2479

–

2480

.

doi:10.1182/blood-2022-163493

.

20.

Kuo

KHM

,

Layton

D

,

Al-Samkari

H

, et al.

P112: energize and energize-T: two phase 3, randomized, double-blind, placebo-controlled studies of mitapivat in adults with non-transfusion-dependent or transfusion-dependent alpha- or beta-thalassemia

.

Hemasphere

.

2022

Jan

31

;

6(suppl)

:

23

-

24

.

doi:10.1097/01.HS9.0000821540.81071.fa

.

21.

Forsyth

S

,

Schroeder

P

,

Geib

J

, et al.

Safety, pharmacokinetics, and pharmacodynamics of etavopivat (FT-4202), an allosteric activator of pyruvate kinase-R, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-human phase 1 trial

.

Clin Pharm Drug Dev

.

2022

;

11

(

5

):

654

-

665

.

doi:10.1002/cpdd.1058

.

22.

Lal

A

,

Brown

C

,

Coates

T

, et al.

S103: trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the PKR activator etavopivat (FT-4202) in patients with thalassemia or sickle cell disease

.

Hemasphere

.

2022

;

6

(

Suppl

):

2

.

doi:10.1097/01.HS9.0000821380.12178.0d

.